Filter
795
Text search:
vaccine
trial
Featured
94
160
Language
Document type
321
169
154
44
41
25
14
10
10
4
1
1
1
Countries / Regions
38
27
18
17
17
13
13
13
12
12
11
10
10
9
8
8
8
8
8
7
7
7
7
6
6
6
5
5
5
5
4
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
210
94
54
35
17
8
2
Toolboxes
195
72
51
49
41
20
19
15
14
11
10
10
10
9
9
8
7
7
6
6
5
2
1
This guidance document provides basic principles for a spokesperson of any health authority on how to respond to vocal vaccine deniers. The suggestions are based on psychological research on persuasion, on research in public health, communication st
...
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and a
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the back
...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored
...
An example of integration of research into epidemic response.
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition
...
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Herd immunity by mass vaccination offers the potential to substantially limit the continuing spread of COVID-19, but high levels of vaccine hesitancy threaten this goal. In a cross-country analysis of vacc
...
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita
...
COVID-19 Vaccine Resource Center
recommended
A collection of resources on Covid-19 vaccines, including frequently asked questions, continuing medical education, published research, and commentary.
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this
...
